Skip to content

Intra-arterial chemotherapy

TL;DR — Intra-arterial chemotherapy (IAC/OAC) delivers melphalan, often with topotecan or carboplatin, through the ophthalmic artery to increase ocular exposure and reduce systemic exposure. A multicentre randomized trial in advanced unilateral disease found higher two-year progression-free globe salvage with IAC than intravenous VEC, but arterial stenosis/occlusion remained route-specific harms. Most earlier evidence is single-centre and eye-level. IAC is a specialised procedure requiring paediatric anaesthesia, neurointerventional skill, vascular access and rescue plans; it is not a globally portable synonym for better care.

Decision-relevant evidence

  • In 143 randomized children with unilateral group D/E disease and no high-risk clinical factors, two-year progression-free globe salvage was 53% (38/72) with IAC versus 27% (19/71) with intravenous chemotherapy; RR 1.97 (95% CI 1.27–3.07, p=0.0020), with no difference in overall survival (Wen 2023, PMID 37536351).

  • Myelosuppression occurred in 51% (37/72) versus 70% (50/71) (RR 0.73, 95% CI 0.56–0.96, p=0.021) and was less severe (p for trend = 0.0070), while IAC produced ophthalmic-artery occlusion in 3% (2/72) and stenosis in 18% (13/72) (PMID 37536351).

  • Pooled observational performance sits close to the trial. A meta-analysis of 43 studies and 3,174 eyes gave overall globe salvage 73% (95% CI 68–77), 69% (63–75) as primary and 66% (58–74) as secondary treatment, with group D at 66% (60–71) versus group E at 49% (39–59); heterogeneity was significant (p < 0.001) and a leave-one-out analysis found no improvement in salvage with time at a single centre, so a "learning curve" is not visible in the published data (Weinberger 2025, PMID 40541288).

  • In a 70-eye case series, primary IAC globe salvage was 72% overall, including 100% for group B, 100% for group C, 94% for group D and 36% for group E; secondary salvage was 62%. Complications per catheterisation (n = 198) included vitreous haemorrhage 2%, branch retinal artery obstruction 1%, ophthalmic artery obstruction 2%, partial choroidal ischaemia 2% and optic neuropathy under 1%, with combined ischaemic complications falling to 1% over the last three years (Shields 2014, PMID 24656794).

  • In 112 group D eyes, enucleation and EBRT were avoided in 78.6% (88/112), including 85.1% (40/47) of treatment-naive, 72.4% (42/58) of previously treated and 85.7% (6/7) of bridge-therapy eyes; Kaplan-Meier globe salvage at 110 months was 74% overall and 85% in the treatment-naive subgroup, and no child died of metastatic disease (Abramson 2016, PMID 26756643).

  • The largest single-centre prospective registry reported catheterisation success in 98.5% of procedures across 95 eyes and 289 injections, with two-year ocular event-free survival 70.0% (95% CI 57.9–82.2) overall, 81.7% (66.8–96.6) for primary IAC and 58.4% (39.5–77.2) after failed intravenous chemotherapy or radiotherapy, and no permanent extraocular complications (Gobin 2011, PMID 21320950).

  • Technical success is not transportable. In the Children's Oncology Group multi-institutional feasibility study ARET12P1, nine institutions enrolled 14 patients and only 67% met the feasibility goal of three ophthalmic-artery injections: the artery could not be accessed for the second injection in two patients and for the first in one, and one patient had grade 4 hypotension during the procedure. The authors explicitly caution centres planning to start IAC (Chintagumpala 2024, PMID 37817345).

  • Real-world results in lower-resource settings are correspondingly lower and stage-dependent: in 20 eyes treated with 67 melphalan-based sessions in Jordan, 95% showed initial regression but long-term salvage was 55%, falling with advanced stage (group D/E 43% versus group C 83%, p = 0.047), vitreous seeding (38% versus 75%, p = 0.046), secondary rather than primary use (46% versus 71%, p = 0.047) and more than three cycles (20% versus 67%, p = 0.034) (Yousef 2025, PMID 40563605). A 357-eye Brazilian series over 13 years reported Kaplan-Meier ocular survival of 90% at one year, 89% at two and 86% at five, with no difference by indication (primary 88%, secondary 85%, bridge 89%; P = 0.52) (Teixeira 2025, PMID 39971005).

  • As salvage after failed prior therapy, a systematic review of 24 studies, 1,366 patients and 1,757 eyes found globe salvage in 776 of 1,184 secondarily treated eyes (64%), cannulation success 71.8–100%, metastatic disease in 2.6% and death in 3% over 7–74 months, with vitreous haemorrhage 13.2%, eyelash loss 12.7% and periocular oedema 10.5% the commonest ocular complications and nausea/vomiting 20.5% and neutropenia 14.1% the commonest systemic ones (Runnels 2021, PMID 33826082).

  • Prospective first-line use has been reported outside the randomized trial: 39 patients with unilateral group B/C/D disease (excluding massive vitreous seeding) entered a phase 2 study of selective ophthalmic-artery melphalan with laser and cryotherapy, median 3.9 cycles, median melphalan 4.9 mg per procedure, median dose–area product 1.24 Gy·cm² per procedure and median follow-up 63 months — the radiation dose per procedure being a quantity most retrospective series omit (Lumbroso-Le Rouic 2021, PMID 34000459).

  • Whether more drugs help is unsettled: a 38-eye single-institution cohort comparing single-agent melphalan with triple-agent melphalan–topotecan–carboplatin found additional eye-saving treatment needed in 69% versus 70% of eyes (P = .983) (Alshahrani 2025, PMID 39395595).

  • Visual function after IAC can be preserved when the foveola starts healthy: in a 27-catheterisation cohort of relapsed eyes, no child had severe visual loss on age-appropriate testing over median 20.9 months, post-IAC pattern visual evoked potentials were normal in all eight tested and all but one electroretinogram was normal — but six patients had severe physiological reactions requiring adrenaline during catheterisation and the ophthalmic artery was difficult to access in 7 of 27 attempts (Reddy 2017, PMID 28432112).

Clinical and research frame

Domain Operational meaning Evidence boundary
Access Femoral arterial catheterisation Bleeding, thrombosis, anaesthesia
Delivery Ophthalmic artery or alternate route Technical failure and non-target exposure
Agents Melphalan ± topotecan/carboplatin Dose varies by age/center
Eye endpoint Progression-free globe salvage Not equal to useful vision
Child endpoint Metastasis, survival, systemic toxicity Rare outcomes need large follow-up

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
37536351 2023 Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. Topic-resolved source (Wen 2023, PMID 37536351)
24656794 2014 Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Topic-resolved source (Shields 2014, PMID 24656794)
26756643 2016 Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. Topic-resolved source (Abramson 2016, PMID 26756643)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
29698399 2018 Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery. Topic-resolved source (Rowlands 2018, PMID 29698399)
25405236 2014 Update on intra-arterial chemotherapy for retinoblastoma. Topic-resolved source (Zanaty 2014, PMID 25405236)
33826082 2021 The role for intra-arterial chemotherapy for refractory retinoblastoma: a systematic review. Topic-resolved source (Runnels 2021, PMID 33826082)
39955086 2025 Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients. Topic-resolved source (He 2025, PMID 39955086)
31954049 2020 Experience of selective intra-arterial chemotherapy for Retinoblastoma. Topic-resolved source (Khaqan 2020, PMID 31954049)
39395595 2025 Single- Versus Triple-Agent Intra-Arterial Chemotherapy for Retinoblastoma. Topic-resolved source (Alshahrani 2025, PMID 39395595)
40563605 2025 Intra-Arterial Melphalan Chemotherapy for Retinoblastoma in a Developing Nation: Real-World Outcomes and Prognostic Factors. Topic-resolved source (Yousef 2025, PMID 40563605)
30334950 2018 Intra-arterial chemotherapy for unilateral advanced intraocular retinoblastoma: Results and short-term complications. Topic-resolved source (Wang 2018, PMID 30334950)
42553724 2026 Intra-arterial chemotherapy for retinoblastoma: a structured narrative review. Topic-resolved source (Ren 2026, PMID 42553724)
37380354 2024 Efficacy of a prolonged stability melphalan formulation for intra-arterial treatment of retinoblastoma. Topic-resolved source (Jubran 2024, PMID 37380354)
30643921 2019 Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study. Topic-resolved source (Stenzel 2019, PMID 30643921)
20381868 2010 Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Topic-resolved source (Abramson 2010, PMID 20381868)
27874261 2017 Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study. Topic-resolved source (Chen 2017, PMID 27874261)
24868582 2014 Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study. Topic-resolved source (Parareda 2014, PMID 24868582)
22197434 2012 Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Topic-resolved source (Muen 2012, PMID 22197434)
21320950 2011 Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Topic-resolved source (Gobin 2011, PMID 21320950)
28513496 2017 Intra-arterial chemotherapy for retinoblastoma: Two-year results from tertiary eye-care center in India. Topic-resolved source (Rishi 2017, PMID 28513496)
39971005 2025 Intra-arterial Chemotherapy for Retinoblastoma, Outcomes Analysis in 357 Eyes: Thirteen Years of Experience in a Referral Center in Brazil. Topic-resolved source (Teixeira 2025, PMID 39971005)
26044473 2015 Intra-arterial chemotherapy for retinoblastoma: First Indian report. Topic-resolved source (Rishi 2015, PMID 26044473)
28432112 2017 Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. Topic-resolved source (Reddy 2017, PMID 28432112)
40881098 2025 Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India. Topic-resolved source (Das 2025, PMID 40881098)
29516970 2018 Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China. Topic-resolved source (Hua 2018, PMID 29516970)
41700592 2026 Intravenous chemotherapy versus intra-arterial chemotherapy for retinoblastoma. Topic-resolved source (Rokohl 2026, PMID 41700592)
39701510 2025 The Role of Intravitreal Chemotherapy as an Adjunctive Treatment for Retinoblastoma: A Systematic Review and Single-Arm Meta-Analysis. Topic-resolved source (Bravo-Gonzalez 2025, PMID 39701510)
33120616 2020 Modern treatment of retinoblastoma: A 2020 review. Topic-resolved source (Ancona-Lezama 2020, PMID 33120616)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
39922380 2025 High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes. Topic-resolved source (Kurian 2025, PMID 39922380)
28730089 2017 An international survey of classification and treatment choices for group D retinoblastoma. Topic-resolved source (Scelfo 2017, PMID 28730089)
38830602 2024 Evolving criteria for group E retinoblastoma: impact on outcomes. Topic-resolved source (Singh 2024, PMID 38830602)
40993900 2025 Intra-arterial Chemotherapy for Retinoblastoma: Real-world Experience. Topic-resolved source (Das 2025, PMID 40993900)
39388193 2024 Survival and Health Care Burden of Children With Retinoblastoma in Europe. Topic-resolved source (Virgili 2024, PMID 39388193)
38492167 2024 Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Singh 2024, PMID 38492167)
34958963 2022 Aqueous Seeding in Retinoblastoma: Classification and Clinicopathologic Correlation. Topic-resolved source (Jakati 2022, PMID 34958963)
38688458 2024 Advanced intraocular retinoblastoma: evolving criteria for group E disease. Topic-resolved source (Sedaghat 2024, PMID 38688458)
39735524 2024 Retinoblastoma in Ethiopian Children: Imaging Findings and Staging. Topic-resolved source (Woldeyohannes 2024, PMID 39735524)
27981923 2016 Tumor Regression Patterns in Retinoblastoma. Topic-resolved source (Zafar 2016, PMID 27981923)
40541288 2025 Intra-arterial chemotherapy for retinoblastoma: a performance analysis. Added by audit 2026-09-01 (Weinberger 2025, PMID 40541288)
37817345 2024 A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Added by audit 2026-09-01 (Chintagumpala 2024, PMID 37817345)
34000459 2021 Selective Ophthalmic Artery Chemotherapy with Melphalan in the Management of Unilateral Retinoblastoma: A Prospective Study. Added by audit 2026-09-01 (Lumbroso-Le Rouic 2021, PMID 34000459)

Source chronology

Era marker PMID What the record contributes
2010 20381868 Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). (Abramson 2010, PMID 20381868)
2011 21320950 Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. (Gobin 2011, PMID 21320950)
2012 22197434 Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. (Muen 2012, PMID 22197434)
2014 24656794 Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. (Shields 2014, PMID 24656794)
2014 24868582 Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study. (Parareda 2014, PMID 24868582)
2014 25405236 Update on intra-arterial chemotherapy for retinoblastoma. (Zanaty 2014, PMID 25405236)
2015 26044473 Intra-arterial chemotherapy for retinoblastoma: First Indian report. (Rishi 2015, PMID 26044473)
2016 26023180 Retinoblastoma. (Ortiz 2016, PMID 26023180)
2016 26756643 Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. (Abramson 2016, PMID 26756643)
2016 27981923 Tumor Regression Patterns in Retinoblastoma. (Zafar 2016, PMID 27981923)
2017 27874261 Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study. (Chen 2017, PMID 27874261)
2017 28432112 Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. (Reddy 2017, PMID 28432112)
2017 28513496 Intra-arterial chemotherapy for retinoblastoma: Two-year results from tertiary eye-care center in India. (Rishi 2017, PMID 28513496)
2017 28730089 An international survey of classification and treatment choices for group D retinoblastoma. (Scelfo 2017, PMID 28730089)
2018 29516970 Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China. (Hua 2018, PMID 29516970)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Which drug combination maximizes control without vascular/retinal toxicity? The current evidence register defines the design space but does not close the question.

  • What is comparative useful-vision outcome after IAC versus intravenous therapy? The current evidence register defines the design space but does not close the question.

  • Can resource-adapted programs reproduce safety outside high-volume centres? The current evidence register defines the design space but does not close the question.

References

  1. Wen X, et al. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. The Lancet. Child & adolescent health. 2023;7:613-620. PMID 37536351
  2. Shields CL, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121:1453-60. PMID 24656794
  3. Abramson DH, et al. Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. PloS one. 2016;11:e0146582. PMID 26756643
  4. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  5. Rowlands MA, et al. Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery. PloS one. 2018;13:e0195395. PMID 29698399
  6. Zanaty M, et al. Update on intra-arterial chemotherapy for retinoblastoma. TheScientificWorldJournal. 2014;2014:869604. PMID 25405236
  7. Runnels J, et al. The role for intra-arterial chemotherapy for refractory retinoblastoma: a systematic review. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2021;23:2066-2077. PMID 33826082
  8. He X, et al. Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients. The British journal of ophthalmology. 2025;109:888-893. PMID 39955086
  9. Khaqan HA, et al. Experience of selective intra-arterial chemotherapy for Retinoblastoma. JPMA. The Journal of the Pakistan Medical Association. 2020;70:178-182. PMID 31954049
  10. Alshahrani NO, et al. Single- Versus Triple-Agent Intra-Arterial Chemotherapy for Retinoblastoma. American journal of ophthalmology. 2025;269:488-496. PMID 39395595
  11. Yousef YA, et al. Intra-Arterial Melphalan Chemotherapy for Retinoblastoma in a Developing Nation: Real-World Outcomes and Prognostic Factors. Cancers. 2025;17. PMID 40563605
  12. Wang L, et al. Intra-arterial chemotherapy for unilateral advanced intraocular retinoblastoma: Results and short-term complications. Medicine. 2018;97:e12676. PMID 30334950
  13. Ren YH, et al. Intra-arterial chemotherapy for retinoblastoma: a structured narrative review. World journal of pediatric surgery. 2026;9:e001213. PMID 42553724
  14. Jubran JH, et al. Efficacy of a prolonged stability melphalan formulation for intra-arterial treatment of retinoblastoma. Journal of neurointerventional surgery. 2024;16:572-577. PMID 37380354
  15. Stenzel E, et al. Feasibility of intra-arterial chemotherapy for retinoblastoma: experiences in a large single center cohort study. Neuroradiology. 2019;61:351-357. PMID 30643921
  16. Abramson DH, et al. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117:1623-9. PMID 20381868
  17. Chen M, et al. Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study. Acta ophthalmologica. 2017;95:613-618. PMID 27874261
  18. Parareda A, et al. Intra-arterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta ophthalmologica. 2014;92:209-15. PMID 24868582
  19. Muen WJ, et al. Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma. Ophthalmology. 2012;119:611-6. PMID 22197434
  20. Gobin YP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Archives of ophthalmology (Chicago, Ill. : 1960). 2011;129:732-7. PMID 21320950
  21. Rishi P, et al. Intra-arterial chemotherapy for retinoblastoma: Two-year results from tertiary eye-care center in India. Indian journal of ophthalmology. 2017;65:311-315. PMID 28513496
  22. Teixeira LF, et al. Intra-arterial Chemotherapy for Retinoblastoma, Outcomes Analysis in 357 Eyes: Thirteen Years of Experience in a Referral Center in Brazil. Ophthalmology. Retina. 2025;9:798-806. PMID 39971005
  23. Rishi P, et al. Intra-arterial chemotherapy for retinoblastoma: First Indian report. Indian journal of ophthalmology. 2015;63:331-4. PMID 26044473
  24. Reddy MA, et al. Reduction of severe visual loss and complications following intra-arterial chemotherapy (IAC) for refractory retinoblastoma. The British journal of ophthalmology. 2017;101:1704-1708. PMID 28432112
  25. Das A, et al. Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India. World journal of clinical pediatrics. 2025;14:103732. PMID 40881098
  26. Hua J, et al. Intra-arterial chemotherapy as second-line treatment for advanced retinoblastoma: A 2-year single-center study in China. Journal of cancer research and therapeutics. 2018;14:106-110. PMID 29516970
  27. Rokohl AC, et al. Intravenous chemotherapy versus intra-arterial chemotherapy for retinoblastoma. The Cochrane database of systematic reviews. 2026;2:CD013695. PMID 41700592
  28. Bravo-Gonzalez A, et al. The Role of Intravitreal Chemotherapy as an Adjunctive Treatment for Retinoblastoma: A Systematic Review and Single-Arm Meta-Analysis. American journal of ophthalmology. 2025;273:130-140. PMID 39701510
  29. Ancona-Lezama D, et al. Modern treatment of retinoblastoma: A 2020 review. Indian journal of ophthalmology. 2020;68:2356-2365. PMID 33120616
  30. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  31. Kurian DE, et al. High-Risk Retinoblastoma Based on International Classification Systems: Analysis of 1362 Eyes. Ophthalmology. Retina. 2025;9:787-797. PMID 39922380
  32. Scelfo C, et al. An international survey of classification and treatment choices for group D retinoblastoma. International journal of ophthalmology. 2017;10:961-967. PMID 28730089
  33. Singh A, et al. Evolving criteria for group E retinoblastoma: impact on outcomes. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2024;59:e534-e541. PMID 38830602
  34. Das A, et al. Intra-arterial Chemotherapy for Retinoblastoma: Real-world Experience. International ophthalmology clinics. 2025;65:60-67. PMID 40993900
  35. Virgili G, et al. Survival and Health Care Burden of Children With Retinoblastoma in Europe. JAMA ophthalmology. 2024;142:1062-70. PMID 39388193
  36. Singh L, et al. Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1147-1156. PMID 38492167
  37. Jakati S, et al. Aqueous Seeding in Retinoblastoma: Classification and Clinicopathologic Correlation. Ophthalmology. Retina. 2022;6:421-428. PMID 34958963
  38. Sedaghat A, et al. Advanced intraocular retinoblastoma: evolving criteria for group E disease. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2024;59:e635-e641. PMID 38688458
  39. Woldeyohannes AM, et al. Retinoblastoma in Ethiopian Children: Imaging Findings and Staging. Ethiopian journal of health sciences. 2024;34:39-46. PMID 39735524
  40. Zafar SN, et al. Tumor Regression Patterns in Retinoblastoma. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2016;26:896-899. PMID 27981923
  41. Weinberger Y, et al. Intra-arterial chemotherapy for retinoblastoma: a performance analysis. The British journal of ophthalmology. 2025;109:1298-1305. PMID 40541288
  42. Chintagumpala M, et al. A multi-institutional feasibility study of intra-arterial chemotherapy in children with retinoblastoma. A Children's Oncology Group study (COG ARET12P1). Pediatric blood & cancer. 2024;71:e30718. PMID 37817345
  43. Lumbroso-Le Rouic L, et al. Selective Ophthalmic Artery Chemotherapy with Melphalan in the Management of Unilateral Retinoblastoma: A Prospective Study. Ophthalmology. Retina. 2021;5:e30-e37. PMID 34000459